Cargando…
DNA Methylation as a Biomarker for Monitoring Disease Outcome in Patients with Hypovitaminosis and Neurological Disorders
DNA methylation remains an under-recognized diagnostic biomarker for several diseases, including neurodegenerative disorders. In this study, we examined differences in global DNA methylation (5mC) levels in serum samples from patients during the initial- and the follow-up visits. Each patient underw...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9956161/ https://www.ncbi.nlm.nih.gov/pubmed/36833292 http://dx.doi.org/10.3390/genes14020365 |
_version_ | 1784894524718317568 |
---|---|
author | Martínez-Iglesias, Olaia Naidoo, Vinogran Corzo, Lola Pego, Rocío Seoane, Silvia Rodríguez, Susana Alcaraz, Margarita Muñiz, Adriana Cacabelos, Natalia Cacabelos, Ramón |
author_facet | Martínez-Iglesias, Olaia Naidoo, Vinogran Corzo, Lola Pego, Rocío Seoane, Silvia Rodríguez, Susana Alcaraz, Margarita Muñiz, Adriana Cacabelos, Natalia Cacabelos, Ramón |
author_sort | Martínez-Iglesias, Olaia |
collection | PubMed |
description | DNA methylation remains an under-recognized diagnostic biomarker for several diseases, including neurodegenerative disorders. In this study, we examined differences in global DNA methylation (5mC) levels in serum samples from patients during the initial- and the follow-up visits. Each patient underwent a blood analysis and neuropsychological assessments. The analysis of 5mC levels revealed two categories of patients; Group A who, during the follow-up, had increased 5mC levels, and Group B who had decreased 5mC levels. Patients with low Fe-, folate-, and vitamin B12- levels during the initial visit showed increased levels of 5mC after treatment when assessed during the follow-up. During the follow-up, 5mC levels in Group A patients increased after treatment for hypovitaminosis with the nutraceutical compounds Animon Complex and MineraXin Plus. 5mC levels were maintained during the follow-up in Group A patients treated for neurological disorders with the bioproducts AtreMorine and NeoBrainine. There was a positive correlation between 5mC levels and MMSE scores, and an inverse correlation between 5mC and ADAS-Cog scores. This expected correlation was observed in Group A patients only. Our study appears to indicate that 5mC has a diagnostic value as a biomarker across different pathologies. |
format | Online Article Text |
id | pubmed-9956161 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99561612023-02-25 DNA Methylation as a Biomarker for Monitoring Disease Outcome in Patients with Hypovitaminosis and Neurological Disorders Martínez-Iglesias, Olaia Naidoo, Vinogran Corzo, Lola Pego, Rocío Seoane, Silvia Rodríguez, Susana Alcaraz, Margarita Muñiz, Adriana Cacabelos, Natalia Cacabelos, Ramón Genes (Basel) Article DNA methylation remains an under-recognized diagnostic biomarker for several diseases, including neurodegenerative disorders. In this study, we examined differences in global DNA methylation (5mC) levels in serum samples from patients during the initial- and the follow-up visits. Each patient underwent a blood analysis and neuropsychological assessments. The analysis of 5mC levels revealed two categories of patients; Group A who, during the follow-up, had increased 5mC levels, and Group B who had decreased 5mC levels. Patients with low Fe-, folate-, and vitamin B12- levels during the initial visit showed increased levels of 5mC after treatment when assessed during the follow-up. During the follow-up, 5mC levels in Group A patients increased after treatment for hypovitaminosis with the nutraceutical compounds Animon Complex and MineraXin Plus. 5mC levels were maintained during the follow-up in Group A patients treated for neurological disorders with the bioproducts AtreMorine and NeoBrainine. There was a positive correlation between 5mC levels and MMSE scores, and an inverse correlation between 5mC and ADAS-Cog scores. This expected correlation was observed in Group A patients only. Our study appears to indicate that 5mC has a diagnostic value as a biomarker across different pathologies. MDPI 2023-01-30 /pmc/articles/PMC9956161/ /pubmed/36833292 http://dx.doi.org/10.3390/genes14020365 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Martínez-Iglesias, Olaia Naidoo, Vinogran Corzo, Lola Pego, Rocío Seoane, Silvia Rodríguez, Susana Alcaraz, Margarita Muñiz, Adriana Cacabelos, Natalia Cacabelos, Ramón DNA Methylation as a Biomarker for Monitoring Disease Outcome in Patients with Hypovitaminosis and Neurological Disorders |
title | DNA Methylation as a Biomarker for Monitoring Disease Outcome in Patients with Hypovitaminosis and Neurological Disorders |
title_full | DNA Methylation as a Biomarker for Monitoring Disease Outcome in Patients with Hypovitaminosis and Neurological Disorders |
title_fullStr | DNA Methylation as a Biomarker for Monitoring Disease Outcome in Patients with Hypovitaminosis and Neurological Disorders |
title_full_unstemmed | DNA Methylation as a Biomarker for Monitoring Disease Outcome in Patients with Hypovitaminosis and Neurological Disorders |
title_short | DNA Methylation as a Biomarker for Monitoring Disease Outcome in Patients with Hypovitaminosis and Neurological Disorders |
title_sort | dna methylation as a biomarker for monitoring disease outcome in patients with hypovitaminosis and neurological disorders |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9956161/ https://www.ncbi.nlm.nih.gov/pubmed/36833292 http://dx.doi.org/10.3390/genes14020365 |
work_keys_str_mv | AT martineziglesiasolaia dnamethylationasabiomarkerformonitoringdiseaseoutcomeinpatientswithhypovitaminosisandneurologicaldisorders AT naidoovinogran dnamethylationasabiomarkerformonitoringdiseaseoutcomeinpatientswithhypovitaminosisandneurologicaldisorders AT corzolola dnamethylationasabiomarkerformonitoringdiseaseoutcomeinpatientswithhypovitaminosisandneurologicaldisorders AT pegorocio dnamethylationasabiomarkerformonitoringdiseaseoutcomeinpatientswithhypovitaminosisandneurologicaldisorders AT seoanesilvia dnamethylationasabiomarkerformonitoringdiseaseoutcomeinpatientswithhypovitaminosisandneurologicaldisorders AT rodriguezsusana dnamethylationasabiomarkerformonitoringdiseaseoutcomeinpatientswithhypovitaminosisandneurologicaldisorders AT alcarazmargarita dnamethylationasabiomarkerformonitoringdiseaseoutcomeinpatientswithhypovitaminosisandneurologicaldisorders AT munizadriana dnamethylationasabiomarkerformonitoringdiseaseoutcomeinpatientswithhypovitaminosisandneurologicaldisorders AT cacabelosnatalia dnamethylationasabiomarkerformonitoringdiseaseoutcomeinpatientswithhypovitaminosisandneurologicaldisorders AT cacabelosramon dnamethylationasabiomarkerformonitoringdiseaseoutcomeinpatientswithhypovitaminosisandneurologicaldisorders |